Was the GLP-1 Problem Always Cost? - Takeaway - MDSpire
Commentary & Perspectives

Was the GLP-1 Problem Always Cost?

A JAMA Viewpoint argues the BALANCE model targets the leading cause of discontinuation.

Share

  • 1

    Sixteen states initially covered GLP-1 medications; four have dropped coverage.

  • 2

    BALANCE model intends to standardize pricing/coverage for obesity-related medications.

  • 3

    Emphasizes obesity as a disease needing urgent acknowledgment.

  • 4

    Financial barriers significantly affect treatment adherence.

  • 5

    Advocacy for participation of state Medicaid and Medicare Part D is essential for success.

  • 6

    Implementation starts in July 2026 with a $50 co-pay for beneficiaries.

Original Source(s)

Was the GLP-1 Problem Always Cost?

  • by Kerri Miller

  • April 3, 2026

Related Content

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

PFAS Exposure Linked to Faster Epigenetic Aging 

Epigenetic clock analysis ties PFNA exposure to faster biological aging, particularly in men aged 50–64 

  • April 1, 2026

  • 2 min
Prednisolone Linked to Metabolic Benefits

A randomized crossover trial found slower bone turnover and no safety differences compared with standard hydrocortisone regimens